| Size | Price | Stock | Qty |
|---|---|---|---|
| 10g |
|
||
| 25g |
|
||
| Other Sizes |
| Targets |
Capriphenone itself does not have a specific pharmacological target as it is primarily a synthetic intermediate rather than a therapeutic agent. Its value lies in its use as a building block for the synthesis of various bioactive compounds, including antibacterial, antifungal, antiviral, and antituberculous agents. The compound's chemical structure allows for further functionalization to create molecules with diverse biological activities.
|
|---|---|
| ln Vitro |
Capriphenone itself is not known to possess direct therapeutic activity. Its significance is as a synthetic intermediate for the preparation of pharmacologically active compounds. As an aryl ketone, capriphenone can be used in various chemical reactions to introduce functional groups and create more complex molecular structures with potential antibacterial, antifungal, antiviral, or antituberculous activities.
|
| ln Vivo |
There is no reported in vivo activity for capriphenone itself, as it is primarily a chemical intermediate rather than a drug candidate. Its role in drug discovery is indirect, serving as a precursor for the synthesis of compounds that are then evaluated for in vivo activity against various pathogens or disease targets.
|
| Enzyme Assay |
As a chemical intermediate, there are no standardized in vitro enzyme/receptor binding assays for capriphenone itself. The compound's utility is in synthetic chemistry rather than biological assay development. Researchers may use capriphenone as a starting material to synthesize test compounds that are then evaluated in various biological assays.
|
| Cell Assay |
There are no reported in vitro cellular assays for capriphenone itself, as it is not a drug candidate. The compound is used in chemical synthesis to prepare molecules that may subsequently be tested in cellular assays for antibacterial, antifungal, antiviral, or anticancer activities.
|
| Animal Protocol |
There are no reported in vivo animal studies for capriphenone itself, as the compound is a synthetic intermediate rather than a therapeutic agent. Animal studies would be conducted on the final drug candidates synthesized from capriphenone rather than on the intermediate itself.
|
| ADME/Pharmacokinetics |
As a synthetic intermediate, there are no reported pharmacokinetic data for capriphenone. Pharmacokinetic studies would be performed on the final drug molecules synthesized from capriphenone rather than on the intermediate itself.
|
| Toxicity/Toxicokinetics |
As a synthetic intermediate used in chemical research and drug discovery, capriphenone is not intended for human consumption, and there are no reported toxicity data for the compound itself. Toxicology studies would be conducted on the final drug candidates synthesized from capriphenone. Appropriate safety precautions should be followed when handling capriphenone in the laboratory.
|
| Additional Infomation |
Capriphenone is a chemical intermediate used in the synthesis of antibacterial, antifungal, antiviral, and antituberculous products. It is an aryl ketone (decanophenone) that serves as a valuable building block in medicinal chemistry for the preparation of more complex bioactive molecules. The compound's CAS number is 6048-82-4 and it has a molecular weight of 232.37.
|
| Molecular Formula |
C16H24O
|
|---|---|
| Molecular Weight |
232.37
|
| Exact Mass |
232.183
|
| CAS # |
6048-82-4
|
| PubChem CID |
80148
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
0.918g/cm3
|
| Boiling Point |
168 °C5 mm Hg(lit.)
|
| Melting Point |
34-36 °C(lit.)
|
| Flash Point |
>230 °F
|
| Index of Refraction |
1.491
|
| LogP |
5.01
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
17
|
| Complexity |
192
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C1C([H])=C([H])C([H])=C([H])C=1[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H]
|
| InChi Key |
QQXJNLYVPPBERR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H24O/c1-2-3-4-5-6-7-11-14-16(17)15-12-9-8-10-13-15/h8-10,12-13H,2-7,11,14H2,1H3
|
| Chemical Name |
1-phenyldecan-1-one
|
| Synonyms |
Ketone, nonyl phenyl Decanophenone Capriphenone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.3035 mL | 21.5174 mL | 43.0348 mL | |
| 5 mM | 0.8607 mL | 4.3035 mL | 8.6070 mL | |
| 10 mM | 0.4303 mL | 2.1517 mL | 4.3035 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
